Syndax Pharmaceutica
SNDX
Delayed Nasdaq - 01/19 10:00:00 pm
10.17USD
+6.16%
Prev.9.5800
Open9.7700
High10.5500
Low9.5000
Volume762 745
Last news
Financials
Sales 2017 2,64 M
EBIT 2017 -60,3 M
R. net 2017 -58,9 M
Tréso. 2017 140 M
Rend. 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 40,8x
EV / Sales 2018 90,7x
Capitalization 248 M
Company
Syndax Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of cancer therapies.It focuses on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.The company...
Sector :
Biopharmaceuticals
Calendar :
2018-03-01 Earnings Release
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBearishBearish
Resistance10,510,511,0
Spread/Res.-3,1%-3,1%-7,3%
Spread/Supp.13%30%27%
Support9,007,808,03